betaxolol has been researched along with Chronic Primary Open Angle Glaucoma in 91 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 9.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension." | 9.17 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. ( Chi, W; Li, A; Wang, S; Zhu, X, 2013) |
| "The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated." | 9.13 | Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. ( Ikeda, Y; Ishibashi, T; Kinoshita, S; Mori, K; Nakajima, N; Naruse, S, 2008) |
| " a significant increase in ophthalmic artery blood flow velocity or a significant decrease in ophthalmic artery resistance index during hypercapnia) underwent medication washout for 4 weeks and were enrolled in a double-masked cross-over study (betaxolol versus timolol)." | 9.09 | Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol. ( Cantor, LB; Evans, DW; Harris, A, 1999) |
| "In a randomized, double-masked study, 41 patients with primary open-angle glaucoma or ocular hypertension were treated with betaxolol 0." | 9.06 | A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. ( Feghali, JG; Kaufman, PL; Mandell, AI; Radius, RL, 1988) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 7.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "Patients with primary open-angle glaucoma (POAG) were dosed twice-daily with 0." | 6.71 | The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol. ( Miki, H; Miki, K, 2004) |
| " The side effect profile of unoprostone appears to be comparable to other established IOP-lowering agents." | 6.70 | A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. ( Kapik, B; Mertz, B; Nordmann, JP; Schwenninger, C; Shams, N; Yannoulis, NC, 2002) |
| " The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0." | 6.68 | A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. ( Serle, JB, 1996) |
| "01) twelve hours after dosing at each observation times." | 6.67 | [Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension]. ( Demailly, P; Denis, P; Saraux, H, 1993) |
| "To date, there have been no reports of cystoid macular edema secondary to timolol, a non-selective beta-adrenergic blocker that apparently has little intrinsic sympathomimetic activity." | 5.27 | Aphakic cystoid macular edema secondary to betaxolol therapy. ( Hesse, RJ; Swan, JL, 1988) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 5.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension." | 5.17 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. ( Chi, W; Li, A; Wang, S; Zhu, X, 2013) |
| "The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated." | 5.13 | Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. ( Ikeda, Y; Ishibashi, T; Kinoshita, S; Mori, K; Nakajima, N; Naruse, S, 2008) |
| " a significant increase in ophthalmic artery blood flow velocity or a significant decrease in ophthalmic artery resistance index during hypercapnia) underwent medication washout for 4 weeks and were enrolled in a double-masked cross-over study (betaxolol versus timolol)." | 5.09 | Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol. ( Cantor, LB; Evans, DW; Harris, A, 1999) |
| "To determine whether dosages of a selective beta-blocking agent (betaxolol) and a topical carbonic anhydrase inhibitor (dorzolamide), sufficient to significantly lower intraocular pressure (IOP), have similar or disparate impact on the retinal and retrobulbar circulation." | 5.09 | A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. ( Arend, O; Cantor, L; Chung, HS; Harris, A; Kagemann, L; Martin, B, 2000) |
| "This study is aimed at establishing the efficacy of the therapeutic agent, betaxolol, in diurnal control of IOP (intraocular pressure)." | 5.08 | Effect of betaxolol on primary open-angle glaucoma and normal-tension glaucoma patients. ( Ciurlo, G; Macrì, A; Rolando, M; Saccà, SC, 1998) |
| "At 1 year, the mean percent reduction in intraocular pressure at peak of 2% dorzolamide, 0." | 5.08 | A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. ( Strahlman, E; Tipping, R; Vogel, R, 1995) |
| " In studies 1 and 2, there was a mean reduction in intraocular pressure from a betaxolol baseline of approximately 3 to 4 mmHg." | 5.08 | Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. ( Robin, AL, 1996) |
| "To assess the safety and intraocular pressure (IOP)-lowering activity of 2% dorzolamide (topical carbonic anhydrase inhibitor), compared to 0." | 5.08 | A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study. ( Ballantyne, C; Gray, TB; Simpson, AJ, 1996) |
| "In a prospective, randomized study, nineteen patients with ocular hypertension (n = 14) or chronic open-angle glaucoma (n = 5) were treated with either betaxolol 0." | 5.07 | Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. ( Collignon-Brach, J, 1994) |
| "Timolol (TIM) and betaxolol (BET) were evaluated for their effects on both intraocular pressure and retinal sensitivity as determined from visual fields in a randomized two-year parallel study in 20 patients with primary open-angle glaucoma." | 5.07 | Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. ( Collignon-Brach, J, 1992) |
| "Betaxolol hydrochloride is a topical beta 1-blocking agent that has been found to be safe and effective in lowering intraocular pressure (IOP) in patients with glaucoma." | 5.06 | Additive effect of betaxolol and epinephrine in primary open angle glaucoma. ( Allen, RC; Epstein, DL, 1986) |
| "In a randomized, double-masked study, 41 patients with primary open-angle glaucoma or ocular hypertension were treated with betaxolol 0." | 5.06 | A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. ( Feghali, JG; Kaufman, PL; Mandell, AI; Radius, RL, 1988) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 3.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "To study the effect of trabeculectomy and monotherapy with topical betaxolol, brimonidine and latanoprost on intraocular pressure (IOP) and pulsatile ocular blood flow (POBF) in patients with normal-pressure glaucoma (NPG)." | 3.71 | Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma. ( Bunce, C; Garway-Heath, DF; Hitchings, RA; Indar, A; Poinoosawmy, D, 2002) |
| "5% twice daily in 39 patients with ocular hypertension or primary open-angle glaucoma already being treated with dipivefrin 0." | 3.67 | Effect of adding betaxolol to dipivefrin therapy. ( Kushner, FH; Ritch, R; Weinreb, RN, 1986) |
| "Betaxolol may cause small changes in the cardiovascular system, suggesting that blood pressure and pulse rates should be checked before and in regular intervals after prescribing it for the elderly." | 2.72 | Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. ( Celik, P; Deveci, HM; Erkin, EF; Kayikçioğlu, O; Sakar, A, 2006) |
| "Patients with primary open-angle glaucoma (POAG) were dosed twice-daily with 0." | 2.71 | The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol. ( Miki, H; Miki, K, 2004) |
| " The side effect profile of unoprostone appears to be comparable to other established IOP-lowering agents." | 2.70 | A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. ( Kapik, B; Mertz, B; Nordmann, JP; Schwenninger, C; Shams, N; Yannoulis, NC, 2002) |
| "Pilocarpine and timolol were not significantly different from each other and both produced a more marked pressure reduction than betaxolol." | 2.69 | A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. ( Drance, SM, 1998) |
| "Betaxolol appears to be an effective and well tolerated ocular hypotensive agent in a typical glaucoma population, which includes many patients with cardiopulmonary disease." | 2.68 | Betaxolol eye drops. A clinical trial of safety and efficacy. ( Goldberg, H; Goldberg, I, 1995) |
| " The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0." | 2.68 | A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. ( Serle, JB, 1996) |
| "01) twelve hours after dosing at each observation times." | 2.67 | [Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension]. ( Demailly, P; Denis, P; Saraux, H, 1993) |
| "Betaxolol appears to be a clinically effective and safe agent in the treatment of open-angle glaucoma." | 2.66 | A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. ( Allen, RC; Epstein, DL; Hertzmark, E; Walker, AM, 1986) |
| "The author investigated 23 patients with primary open angle glaucoma treated with pilocarpine, timolol, betoptic and latanoprost." | 1.31 | [Additive effects of topical carbonic anhydrase inhibitors]. ( Potocký, M, 2001) |
| "Patients with primary open angle glaucoma (N = 16) were retrospectively evaluated to determine changes in visual function, as measured by contrast sensitivity, after beta-blocker therapy." | 1.29 | Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy. ( Evans, DW; Pomerance, GN, 1994) |
| "To date, there have been no reports of cystoid macular edema secondary to timolol, a non-selective beta-adrenergic blocker that apparently has little intrinsic sympathomimetic activity." | 1.27 | Aphakic cystoid macular edema secondary to betaxolol therapy. ( Hesse, RJ; Swan, JL, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (24.18) | 18.7374 |
| 1990's | 31 (34.07) | 18.2507 |
| 2000's | 29 (31.87) | 29.6817 |
| 2010's | 6 (6.59) | 24.3611 |
| 2020's | 3 (3.30) | 2.80 |
| Authors | Studies |
|---|---|
| Sajid Chughtai, FR | 1 |
| Zaman, M | 1 |
| Khan, AH | 1 |
| Amjad, MW | 1 |
| Aman, W | 1 |
| Khan, SM | 1 |
| Ghafoor Raja, MA | 1 |
| Nadeem Alvi, M | 1 |
| Afridi, M | 1 |
| Hanif, M | 1 |
| Lešták, J | 1 |
| Fůs, M | 1 |
| Weissová, I | 1 |
| Marešová, K | 1 |
| Harasymowycz, P | 1 |
| Royer, C | 1 |
| Cui, AX | 1 |
| Barbeau, M | 1 |
| Jobin-Gervais, K | 1 |
| Mathurin, K | 1 |
| Lachaine, J | 1 |
| Beauchemin, C | 1 |
| Chi, W | 1 |
| Li, A | 1 |
| Wang, S | 1 |
| Zhu, X | 1 |
| Öhnell, H | 1 |
| Heijl, A | 11 |
| Brenner, L | 1 |
| Anderson, H | 1 |
| Bengtsson, B | 13 |
| Xu, K | 1 |
| Campbell, EL | 1 |
| Gill, SS | 1 |
| Nesdole, R | 1 |
| Campbell, RJ | 1 |
| Leske, MC | 10 |
| Yang, Z | 3 |
| Dobre, X | 1 |
| Cheng, JW | 1 |
| Cai, JP | 1 |
| Wei, RL | 1 |
| Hyman, L | 6 |
| Nino, M | 1 |
| Napolitano, M | 1 |
| Scalvenzi, M | 1 |
| Peters, D | 1 |
| Poinoosawmy, D | 1 |
| Indar, A | 1 |
| Bunce, C | 1 |
| Garway-Heath, DF | 1 |
| Hitchings, RA | 1 |
| Hussein, M | 3 |
| Lichter, PR | 1 |
| Bullimore, MA | 1 |
| Komaroff, E | 2 |
| Ignat, F | 1 |
| Damian, C | 1 |
| Mănescu, R | 1 |
| Perovic, I | 1 |
| Ohtake, Y | 1 |
| Tanino, T | 1 |
| Kimura, I | 1 |
| Mashima, Y | 1 |
| Oguchi, Y | 1 |
| Nenciu, A | 2 |
| Stefan, C | 2 |
| Ardelean, C | 1 |
| McCarey, BE | 1 |
| Kapik, BM | 1 |
| Kane, FE | 1 |
| Miki, H | 1 |
| Miki, K | 1 |
| Hyman, LG | 1 |
| Erkin, EF | 1 |
| Celik, P | 1 |
| Kayikçioğlu, O | 1 |
| Deveci, HM | 1 |
| Sakar, A | 1 |
| Dong, L | 1 |
| Ikeda, Y | 1 |
| Mori, K | 1 |
| Ishibashi, T | 1 |
| Naruse, S | 1 |
| Nakajima, N | 1 |
| Kinoshita, S | 1 |
| Berrospi, AR | 1 |
| Leibowitz, HM | 1 |
| Berry, DP | 1 |
| Van Buskirk, EM | 1 |
| Shields, MB | 1 |
| Remis, LL | 1 |
| Epstein, DL | 3 |
| Morsman, CD | 1 |
| Bosem, ME | 1 |
| Lusky, M | 1 |
| Weinreb, RN | 3 |
| Goldberg, I | 3 |
| Goldberg, H | 1 |
| Strahlman, E | 1 |
| Tipping, R | 1 |
| Vogel, R | 1 |
| Diggory, P | 2 |
| Cassels-Brown, A | 2 |
| Vail, A | 1 |
| Abbey, LM | 1 |
| Hillman, JS | 1 |
| Carenini, AB | 1 |
| Sibour, G | 1 |
| Boles Carenini, B | 1 |
| Collignon-Brach, J | 3 |
| Kaiser, HJ | 1 |
| Flammer, J | 2 |
| Stümpfig, D | 2 |
| Hendrickson, P | 1 |
| Pomerance, GN | 1 |
| Evans, DW | 2 |
| Denis, P | 1 |
| Demailly, P | 1 |
| Saraux, H | 1 |
| Albracht, DC | 1 |
| LeBlanc, RP | 1 |
| Cruz, AM | 1 |
| Lamping, KA | 1 |
| Siegel, LI | 1 |
| Stern, KL | 1 |
| Kelley, EP | 1 |
| Stoecker, JF | 1 |
| Simpson, AJ | 1 |
| Gray, TB | 1 |
| Ballantyne, C | 1 |
| Serle, JB | 1 |
| Robin, AL | 1 |
| Fernandez, C | 1 |
| Potocký, M | 2 |
| Vodrázková, E | 1 |
| Troiano, P | 1 |
| Cavallotti, B | 1 |
| Iraci, M | 1 |
| Galli, L | 1 |
| Miglior, M | 1 |
| Lamberti, G | 1 |
| Pignalosa, B | 1 |
| Fusco, R | 1 |
| Pignalosa, G | 1 |
| Di Govanni, A | 1 |
| Sebastiani, A | 1 |
| Saccà, SC | 1 |
| Macrì, A | 1 |
| Rolando, M | 1 |
| Ciurlo, G | 1 |
| Drance, SM | 1 |
| Lass, JH | 1 |
| Khosrof, SA | 1 |
| Laurence, JK | 1 |
| Horwitz, B | 1 |
| Ghosh, K | 1 |
| Adamsons, I | 1 |
| Gillies, WE | 1 |
| Brooks, AM | 1 |
| Vainio-Jylhä, E | 1 |
| Vuori, ML | 1 |
| Chai, E | 1 |
| Chia, A | 1 |
| Benscher, C | 1 |
| Bauman, A | 1 |
| Chen, J | 1 |
| Hayreh, SS | 1 |
| Podhajsky, P | 1 |
| Zimmerman, MB | 1 |
| Harris, A | 2 |
| Cantor, LB | 1 |
| Arend, O | 1 |
| Chung, HS | 1 |
| Kagemann, L | 1 |
| Cantor, L | 1 |
| Martin, B | 1 |
| Arici, MK | 1 |
| Arici, DS | 1 |
| Topalkara, A | 1 |
| Güler, C | 1 |
| Javitt, J | 1 |
| Bojic, L | 1 |
| Bagatin, J | 1 |
| Ivanisevic, M | 1 |
| Hozo, I | 1 |
| Racic, G | 1 |
| Karelovic, D | 1 |
| Watson, PG | 1 |
| Barnett, MF | 1 |
| Parker, V | 1 |
| Haybittle, J | 1 |
| Marchetti, A | 1 |
| Magar, R | 1 |
| An, P | 1 |
| Nichol, M | 1 |
| Grehn, F | 1 |
| Nordmann, JP | 1 |
| Mertz, B | 1 |
| Yannoulis, NC | 1 |
| Schwenninger, C | 1 |
| Kapik, B | 1 |
| Shams, N | 1 |
| Balaş, M | 1 |
| Neacşu, A | 1 |
| Lascu, L | 1 |
| Sánchez-Pérez, J | 1 |
| Jesús Del Río, M | 1 |
| Fernández-Villalta, MJ | 1 |
| García-Díez, A | 1 |
| Messmer, C | 1 |
| Wilhelmus, KR | 1 |
| McCulloch, RR | 1 |
| Gross, RL | 1 |
| Caldwell, DR | 1 |
| Goode, SM | 1 |
| Horwitz, BL | 1 |
| Laibovitz, R | 1 |
| Shrader, CE | 1 |
| Stewart, RH | 1 |
| Williams, AT | 1 |
| Pillunat, LE | 1 |
| Stodtmeister, R | 1 |
| Maas, S | 1 |
| Ros, FE | 1 |
| De Heer, LJ | 1 |
| De Keizer, RJ | 1 |
| Allen, RC | 2 |
| Richards, RD | 1 |
| Ball, S | 1 |
| Bleckmann, H | 2 |
| Dorow, P | 2 |
| Kendall, K | 1 |
| Mundorf, T | 1 |
| Nardin, G | 1 |
| Zimmerman, TJ | 1 |
| Hesse, R | 1 |
| Lavin, P | 1 |
| Feghali, JG | 1 |
| Kaufman, PL | 1 |
| Radius, RL | 1 |
| Mandell, AI | 1 |
| Lee, ME | 1 |
| Hesse, RJ | 1 |
| Swan, JL | 1 |
| Pecori-Giraldi, J | 1 |
| Collini, S | 1 |
| Planner-Terzaghi, A | 1 |
| Arrico, L | 1 |
| Grechi, G | 1 |
| Hertzmark, E | 1 |
| Walker, AM | 1 |
| Zabel, RW | 1 |
| MacDonald, IM | 1 |
| Bloom, HR | 1 |
| Cech, JM | 1 |
| Eston, AB | 1 |
| Finegan, JT | 1 |
| Gingold, MP | 1 |
| Meyer, L | 1 |
| Varr, WF | 1 |
| Weinberg, DA | 1 |
| Wilson, C | 1 |
| Zalta, AH | 1 |
| Patorgis, CJ | 1 |
| Magnus, D | 1 |
| Ritch, R | 1 |
| Kushner, FH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000132] | Phase 3 | 0 participants | Interventional | 1992-10-31 | Active, not recruiting | ||
| Effect on the Adherence to Glaucoma Eye Drops by Improving Patient Understanding and Using a Tele-reminder System: A Randomized Controlled Clinical Trial[NCT04317573] | Phase 2 | 59 participants (Actual) | Interventional | 2018-10-19 | Completed | ||
| Evaluation of the Water Drinking Test Response in Supine and Sitting Position Using the Continuous Intraocular Pressure Measurement Device Sensimed Triggerfish in Healthy Subjects[NCT02843971] | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| The PAIR Study. Positive Airway Pressure and Intraocular Relationship: IOP Response to a Short-term Application of CPAP[NCT03127813] | 46 participants (Actual) | Interventional | 2017-02-15 | Terminated (stopped due to After recruiting just over 50% of target an interim review conclude a larger sample size was highly unlikely to alter the study outcomes) | |||
| XEN45 Gel Stent Implantation in Glaucoma Surgery[NCT03138928] | 15 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program[NCT03159247] | 107 participants (Anticipated) | Interventional | 2017-01-12 | Completed | |||
| Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression - A Randomized Control Trial[NCT05940623] | 142 participants (Anticipated) | Interventional | 2023-08-24 | Not yet recruiting | |||
| Non-Contact Air Tonometry (Topcon CT-1®) Versus Goldmann Applanation Tonometry: a Device Comparison Study[NCT03684174] | 58 participants (Actual) | Observational | 2017-04-01 | Completed | |||
| Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye[NCT01348672] | 381 participants (Anticipated) | Observational | 2012-03-31 | Recruiting | |||
| The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation[NCT00705757] | Phase 4 | 89 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Effect of Medically Lowering Intraocular Pressure in Glaucoma Suspects With High Myopia: A Randomized Controlled Trial[NCT04296916] | 264 participants (Anticipated) | Interventional | 2020-04-17 | Recruiting | |||
| Effect of Medically Intraocular Pressure Lowering on Progressive High Myopia[NCT05850936] | 152 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Periocular skin color was measured with the Minolta Chroma Meter CR-400 and the L*a*b* system, also known as Commission Internationale de l'Eclairage. This is a well-accepted unit of measurement in which L* corresponds to brightness and a* and b* correspond to chromaticity.~Measurements were taken at baseline and 1 year. Data from each time point and each location (upper and lower eyelids or cheeks/face) were averaged, and subtracted from the baseline value for that location. Six predetermined areas on and around the upper and lower eyelid and 2 areas of the face/cheek were measured.Upper and lower eyelid values were averaged and reported as single value for each location ie;-upper eyelids, lower eyelid and cheek/face. A decrease in luminance indicates increased pigmentation at the site of measurement." (NCT00705757)
Timeframe: one year
| Intervention | L*a*b* (Mean) | ||
|---|---|---|---|
| Upper Lid | Lower Lid | Cheek/Face | |
| Lumigan | -0.90 | -0.37 | 0.30 |
| Travatan | -0.90 | 0.17 | 0.51 |
| Xalatan | -1.42 | 0.48 | 0.55 |
4 reviews available for betaxolol and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Topics: Amides; Antihypertensive Agents; Bayes Theorem; Betaxolol; Bimatoprost; Brimonidine Tartrate; Carteo | 2022 |
Meta-analysis of medical intervention for normal tension glaucoma.
Topics: Aged; Amides; Antihypertensive Agents; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cloprostenol; F | 2009 |
Treatment of glaucoma.
Topics: Betaxolol; Epinephrine; Glaucoma; Glaucoma, Open-Angle; Humans; Hydroxydopamines; Laser Therapy; Lev | 1984 |
Clinical and economic impact of new trends in glaucoma treatment.
Topics: Adult; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cost-Benefit Analysis; Critical Pat | 2001 |
59 trials available for betaxolol and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Topics: Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Drug Administration Schedule; Drug C | 2013 |
Structural and Functional Progression in the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Betaxolol; Combined Modality Therapy; Diagnostic Techn | 2016 |
Disc hemorrhages and treatment in the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Betaxolol; Combined Modality Therapy; Disease Progression; Follow-Up St | 2008 |
[Analysis of the effectiveness of beta-blockers for intraocular pressure and visual field in primary open-angle glaucoma].
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Retrospe | 2008 |
Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial.
Topics: Aged; Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Disease Progression; Female; Gl | 2011 |
Effects of argon laser trabeculoplasty in the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Betaxolol; Cohort Studies; Disease Progression; Exfoli | 2011 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 2002 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Combined Modality Therapy; Disease | 2003 |
Measuring visual field progression in the Early Manifest Glaucoma Trial.
Topics: Aged; Antihypertensive Agents; Betaxolol; Disease Progression; Glaucoma, Open-Angle; Humans; Intraoc | 2003 |
[Long-term efficacy and safety of combined topical antiglaucoma therapy--timolol & unoprostone vs. betaxolol & unoprostone].
Topics: Adult; Aged; Antihypertensive Agents; Betaxolol; Dinoprost; Drug Therapy, Combination; Female; Glauc | 2004 |
[Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication].
Topics: Administration, Topical; Adrenergic beta-Antagonists; Antihypertensive Agents; Benzalkonium Compound | 2004 |
Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Dinoprost; Double-Blind Method; | 2004 |
The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol.
Topics: Adult; Aged; Antihypertensive Agents; Betaxolol; Female; Glaucoma, Open-Angle; Humans; Intraocular P | 2004 |
Treatment and vision-related quality of life in the early manifest glaucoma trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Cross-Sectio | 2005 |
Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Blood Pressure; Cardiovascular S | 2006 |
Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Combined Modality Therapy; Disease Prog | 2007 |
Predictors of long-term progression in the early manifest glaucoma trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Blood Pressure; Cardiovascular Diseases | 2007 |
Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Carteolol; Female; Glaucoma, Open-A | 2008 |
Betaxolol and timolol. A comparison of efficacy and side effects.
Topics: Aged; Betaxolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Glaucoma, Op | 1984 |
The effect of topical beta-adrenoceptor blocking agents on pulsatile ocular blood flow.
Topics: Adrenergic beta-Antagonists; Betaxolol; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Press | 1995 |
Betaxolol eye drops. A clinical trial of safety and efficacy.
Topics: Aged; Aged, 80 and over; Betaxolol; Cardiovascular Diseases; Drug Tolerance; Female; Glaucoma, Open- | 1995 |
A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Betaxolol; Carbonic Anhydrase I | 1995 |
Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents.
Topics: Aged; Aged, 80 and over; Betaxolol; Cross-Over Studies; Epinephrine; Exercise Tolerance; Female; For | 1995 |
Differences in the longterm effect of timolol and betaxolol on the pulsatile ocular blood flow.
Topics: Adult; Aged; Aged, 80 and over; Betaxolol; Blood Flow Velocity; Female; Glaucoma, Open-Angle; Humans | 1994 |
Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma.
Topics: Administration, Topical; Adult; Aged; Betaxolol; Chronic Disease; Female; Glaucoma, Open-Angle; Huma | 1994 |
Longterm visual field follow-up of glaucoma patients treated with beta-blockers.
Topics: Aged; Betaxolol; Blood Pressure; Double-Blind Method; Female; Follow-Up Studies; Glaucoma, Open-Angl | 1994 |
[Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension].
Topics: Adult; Benzalkonium Compounds; Betaxolol; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; | 1993 |
A double-masked comparison of betaxolol and dipivefrin for the treatment of increased intraocular pressure.
Topics: Aged; Betaxolol; Double-Blind Method; Epinephrine; Female; Glaucoma, Open-Angle; Heart Rate; Humans; | 1993 |
A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Carbonic Anhydrase Inhibitor | 1996 |
A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; B | 1996 |
Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Double-Blind Method; Drug Therapy, Combination; Female | 1996 |
Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Airway Resistance; Betaxolol; Blood Pressure; | 1996 |
[Beta-blockers in the treatment of open-angle glaucoma].
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Levobuno | 1996 |
Pressure-reducing efficacy and tolerability of betaxolol in ionic solution.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Female; Follow-Up Studies; Glaucoma, Open-Angle; Human | 1997 |
Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic | 1997 |
Effect of betaxolol on primary open-angle glaucoma and normal-tension glaucoma patients.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Aqueous Humor; Betaxolol; Circadian Rhythm; Femal | 1998 |
A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Double-Blind Method; Female; Glaucoma, Open-Angle; Hum | 1998 |
A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Carbonic Anhydrase Inhibitor | 1998 |
The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Double-Blind Method; F | 1999 |
Early Manifest Glaucoma Trial: design and baseline data.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 1999 |
Early Manifest Glaucoma Trial: design and baseline data.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 1999 |
Early Manifest Glaucoma Trial: design and baseline data.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 1999 |
Early Manifest Glaucoma Trial: design and baseline data.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Disease Progression; Female; Glauco | 1999 |
Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol.
Topics: Adrenergic beta-Antagonists; Betaxolol; Cross-Over Studies; Double-Blind Method; Eye; Female; Glauco | 1999 |
A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Blood Flow Velocity; Carboni | 2000 |
Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; B | 2000 |
Influence of betaxolol and timolol on the venous tone in glaucoma patients.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aged; Betaxolol; Blood Pressure; Female; Glauc | 1999 |
A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Carteolol; Drug Therapy, Combination; Female; Glaucoma | 2001 |
Clinical and economic impact of new trends in glaucoma treatment.
Topics: Adult; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cost-Benefit Analysis; Critical Pat | 2001 |
A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Dinoprost; Double-Blind Method; Exf | 2002 |
[Non surgical alternatives in the treatment of the primitive open angle glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Glauco | 2001 |
Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma.
Topics: Aged; Betaxolol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Longitudinal Studies; M | 1992 |
[Effect of betaxolol and timolol on visual fields in glaucoma patients].
Topics: Betaxolol; Double-Blind Method; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ophthalmic Solut | 1991 |
A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.
Topics: Administration, Topical; Analysis of Variance; Betaxolol; Dose-Response Relationship, Drug; Double-B | 1990 |
Early visual field changes with beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Drug Evaluation, Preclinical; Follow-Up Studies; | 1989 |
Efficacy and safety of the combination therapy Pilogel/beta-blocker: interim results.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Circadian Rhythm; Clinical Trials as Topic; Drug Thera | 1989 |
Two new beta-blockers for glaucoma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Clinical Trials as Topic; Double-Bl | 1986 |
Additive effect of betaxolol and epinephrine in primary open angle glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Clinical Trials as Topic; Double-Blind Method; | 1986 |
[Treatment with betaxolol and placebo eyedrops in patients with glaucoma and reactive airway diseases].
Topics: Adrenergic beta-Antagonists; Betaxolol; Bronchial Provocation Tests; Clinical Trials as Topic; Doubl | 1987 |
A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Betaxolol; Clinical Trials as Topic; Double-Blind Method; Female | 1988 |
[Timolol, betaxolol and befunolol in the treatment of glaucoma. Study of their bronchopulmonary effects].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Clinical Trials as Topic; Female; Forced Expira | 1988 |
A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma.
Topics: Adult; Aged; Betaxolol; Clinical Trials as Topic; Double-Blind Method; Female; Glaucoma, Open-Angle; | 1986 |
29 other studies available for betaxolol and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Formulation and evaluation of sustained release ocular inserts of betaxolol hydrochloride using arabinoxylan from Plantago ovata.
Topics: Administration, Ophthalmic; Adrenergic beta-1 Receptor Antagonists; Alginates; Betaxolol; Delayed-Ac | 2021 |
Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma.
Topics: Betaxolol; Carteolol; Evoked Potentials, Visual; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular | 2020 |
Impact of Combination Glaucoma Therapies on β-Blocker Exposure.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Drug Combinations; Drug Prescriptions; Drug Utilizatio | 2017 |
Allergic contact dermatitis due to the beta-blocker betaxolol in eyedrops, with cross-sensitivity to timolol.
Topics: Adrenergic beta-Antagonists; Betaxolol; Dermatitis, Allergic Contact; Glaucoma, Open-Angle; Humans; | 2010 |
Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
Topics: Administration, Topical; Aged; Antihypertensive Agents; Betaxolol; Blood Flow Velocity; Brimonidine | 2002 |
Expectations from clinical trials: results of the Early Manifest Glaucoma Trial.
Topics: Betaxolol; Clinical Trials as Topic; Disease Progression; Glaucoma, Open-Angle; Humans; Laser Therap | 2002 |
To treat or not to treat? That is the question.
Topics: Betaxolol; Disease Progression; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser Therapy; T | 2002 |
[Neuroprotective effect of Betoptic S-considerations after 18 months of treatment].
Topics: Antihypertensive Agents; Betaxolol; Computer Graphics; Glaucoma, Open-Angle; Humans; Retrospective S | 2002 |
Betaxolol. A new beta-adrenergic blocking agent for treatment of glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Blood Pressure; Female; Glaucoma, Open-Angle; Humans; | 1982 |
Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy.
Topics: Aged; Betaxolol; Contrast Sensitivity; Glaucoma, Open-Angle; Humans; Levobunolol; Middle Aged; Repro | 1994 |
An in-service investigation of the additive effect of topical adrenergic agonists and beta-blockers.
Topics: Administration, Topical; Adrenergic Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and | 1998 |
The Hettinger hand vibration test, vasospasm, and glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Diagnostic Techniques, Ophthalmological; Female | 1999 |
Beta-blocker eyedrops and nocturnal arterial hypotension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Circadian Rh | 1999 |
Adverse effects of topical antiglaucoma drugs on the ocular surface.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Conjunctiva; Epinephrine; Glaucoma, Open-Angle; | 2000 |
[Additive effects of topical carbonic anhydrase inhibitors].
Topics: Aged; Betaxolol; Carbonic Anhydrase Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; G | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; | 2001 |
Positive use test in contact dermatitis from betaxolol hydrochloride.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Dermatitis, Allergic Contact; Facia | 2002 |
Dendritic keratopathy associated with beta-blocker eyedrops.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Betaxolol; Chronic Disease; Corneal Diseases; | 1990 |
Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs.
Topics: Acetazolamide; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Glaucoma, Open-Angle; Hu | 1989 |
Glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma; Glaucoma, Open-Angle; Humans; Infant, Newborn; Las | 1987 |
Congestive heart failure from betaxolol. Case report.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Glaucoma, Open-Angle; Heart Failure | 1987 |
[Locally applied cardioselective beta blocker and histamine provocation in patients with obstructive airway disease].
Topics: Adrenergic beta-Antagonists; Betaxolol; Bronchial Provocation Tests; Forced Expiratory Volume; Glauc | 1987 |
Tolerability of timolol and betaxolol in patients with chronic open-angle glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic Disease; Drug Tolerance; Eye; Female; G | 1987 |
Beta adrenergic blocking agents for open-angle glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Glaucoma, Open-Angle; Humans; Levobunolol; Propanolamines; T | 1988 |
Aphakic cystoid macular edema secondary to betaxolol therapy.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Cataract Extraction; Female; Glauco | 1988 |
Sinus arrest associated with betaxolol ophthalmic drops.
Topics: Betaxolol; Female; Glaucoma, Open-Angle; Heart Arrest; Humans; Middle Aged; Ophthalmic Solutions; Pr | 1987 |
Additive effect of betaxolol and epinephrine in primary open angle glaucoma.
Topics: Betaxolol; Drug Synergism; Epinephrine; Glaucoma, Open-Angle; Humans; Propanolamines | 1987 |
New drug therapy in open-angle glaucoma.
Topics: Betaxolol; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Glaucoma, Open-Angle; Huma | 1986 |
Effect of adding betaxolol to dipivefrin therapy.
Topics: Aged; Betaxolol; Drug Therapy, Combination; Epinephrine; Female; Glaucoma, Open-Angle; Humans; Male; | 1986 |